GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » Shiller PE Ratio

Esperion Therapeutics (Esperion Therapeutics) Shiller PE Ratio : (As of May. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Esperion Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Esperion Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Esperion Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Shiller PE Ratio Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Esperion Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Shiller PE Ratio falls into.



Esperion Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Esperion Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Esperion Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.34/131.7762*131.7762
=0.340

Current CPI (Mar. 2024) = 131.7762.

Esperion Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.600 100.560 -0.786
201409 -0.640 100.428 -0.840
201412 -0.490 99.070 -0.652
201503 -0.560 99.621 -0.741
201506 -0.550 100.684 -0.720
201509 -0.570 100.392 -0.748
201512 -0.580 99.792 -0.766
201603 -0.650 100.470 -0.853
201606 -0.620 101.688 -0.803
201609 -0.770 101.861 -0.996
201612 -1.290 101.863 -1.669
201703 -1.800 102.862 -2.306
201706 -1.920 103.349 -2.448
201709 -1.860 104.136 -2.354
201712 -1.440 104.011 -1.824
201803 -1.730 105.290 -2.165
201806 -1.710 106.317 -2.119
201809 -1.860 106.507 -2.301
201812 -2.240 105.998 -2.785
201903 3.070 107.251 3.772
201906 -2.010 108.070 -2.451
201909 -2.520 108.329 -3.065
201912 -2.260 108.420 -2.747
202003 -2.840 108.902 -3.437
202006 4.320 108.767 5.234
202009 -3.070 109.815 -3.684
202012 -3.890 109.897 -4.664
202103 -3.500 111.754 -4.127
202106 -1.670 114.631 -1.920
202109 -2.620 115.734 -2.983
202112 -1.770 117.630 -1.983
202203 -0.930 121.301 -1.010
202206 -1.050 125.017 -1.107
202209 -0.810 125.227 -0.852
202212 -0.760 125.222 -0.800
202303 -0.790 127.348 -0.817
202306 -0.460 128.729 -0.471
202309 -0.370 129.860 -0.375
202312 -0.500 129.419 -0.509
202403 0.340 131.776 0.340

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Esperion Therapeutics  (NAS:ESPR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Esperion Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (Esperion Therapeutics) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Executives
Eric Warren officer: Chief Commercial Officer 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Sheldon L. Koenig officer: Chief Operating Officer C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joanne M. Foody officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Benjamin Looker officer: General Counsel C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Benjamin Halladay officer: Chief Financial Officer ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director, officer: Pres & Chief Executive Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121

Esperion Therapeutics (Esperion Therapeutics) Headlines

From GuruFocus

Esperion Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-09-2023